Treatment of multiple eccrine hydrocystomas with botulinum toxin type-A (BT-A)

Efficacy of botulinum toxin type-A (BT-A) in multiple eccrine hydrocystomas

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201105316403N2

Enrollment

Registered

2011-07-15

Start date

2006-07-31

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple eccrine hydrocystomas. Other eccrine sweat disorders

Interventions

Intervention 1: Dysport was injected with 5 units in 1/100 milliliter pre-lesional and intradermaly. Re-treatment are every 6-12 months. Intervention 2: Dysport was injected with 10 units in 1/100 mil

Treatment - Drugs

Dysport was injected with 5 units in 1/100 milliliter pre-lesional and intradermaly. Re-treatment are every 6-12 months

Dysport was injected with 10 units in 1/100 milliliter pre-lesional and intradermaly. Re-treatment are every 6-12 months

Eligibility

Sex/Gender

All

Age

15 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: pathologically documented Exclusion criteria: previous sensitivity to Buttox, Each muscular weakness such as myastina gravis, simultaneous use of any drugs induced muscular weakness

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Improvement. Timepoint: The end of 2th week, 1th, 3th, 6th, 12th months. Method of measurement: clinical observation.	—

Secondary

Measure	Time frame
Complication (ptosis, ecchymosis, facial asymetry). Timepoint: The end 2 week, 1th, 3th, 6th and 12th months. Method of measurement: clinical observation.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026